Alto Neuroscience Gets $50M Boost and FDA Green Light for Depression Treatment
Baird raises Alto Neuroscience price target to $16 as company secures $50M funding and FDA approval to fast-track ALTO-207 depression drug development.
/ 932 items
#Healthcare↓
Rani Therapeutics Stock Soars: Major Partnership and Funding Boost Shares to $10 Target
Maxim doubles Rani Therapeutics price target to $10 after $1B+ Chugai partnership validates RaniPill technology. Company secures $60M funding to advance oral drug delivery platform.
Celcuity Shares Surge After Gedatolisib Shows 76% Reduction in Disease Progression
Celcuity shares jump 45% after Phase 3 trial shows gedatolisib significantly improves survival in HR+/HER2- breast cancer patients. Analysts raise price target to $95.
Bolt Bio & NewAmsterdam Get Buy Ratings from H.C. Wainwright
H.C. Wainwright initiates coverage on Bolt Biotherapeutics and NewAmsterdam Pharma with Buy ratings, highlighting innovative treatments in development.
Olema Stock Crashes on Roche's Shadow, Not Its Own Data
Despite positive palazestrant (OP-1250) trial results, Olema Pharmaceuticals' shares dropped Monday, overshadowed by disappointing outcomes from a Roche breast cancer study.
Replimune Gets FDA Nod for RP1 Drug Resubmission
Replimune's RP1 melanoma treatment gets FDA acceptance for BLA resubmission with April 2026 review date. Wedbush upgrades stock to Outperform with $18 target as approval odds improve.